Entasis Therapeutics   Report issue

For profit Phase 1 Phase 3
Founded: Waltham MA United States (2015)
Status: Acquired by Innovive Pharmaceuticals (2022) → now CytRx (2008)

Organization Overview

First Clinical Trial
2015
NCT02298920
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2019

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Entasis Therapeutics

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Bacteremia (Phase 3)

Communicable Diseases (Phase 2)

Infections (Phase 2)

Pneumonia (Phase 3)

Pneumonia, Bacterial (Phase 3)

Pyelonephritis (Phase 2)

Renal Insufficiency (Phase 1)

Urinary Tract Infections (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 9
  • # of Trial APIs: 9